Trial Profile
Safety and Efficacy of Secukinumab in Adults With Chronic Plaque Type Psoriasis With a PASI Score of 6 to 12
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Oct 2022
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- 30 Aug 2021 Status changed from active, no longer recruiting to completed.
- 05 Jan 2021 Planned End Date changed from 1 Oct 2021 to 28 Feb 2022.
- 05 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 29 Jul 2021.